Form 4: Veracyte Officer Sells Shares Under 10b5-1 Plan

Phillip G. Febbo, Veracyte's Chief Scientific & Medical Officer, sold 8,349 shares of common stock for a weighted average price of $36.0174 per share under a pre-arranged Rule 10b5-1 plan.

Summary

• Phillip G. Febbo, the Chief Scientific & Medical Officer of Veracyte, Inc. (VCYT), reported a sale of common stock.
• The transaction involved the disposition of 8,349 shares of common stock.
• The shares were sold at a weighted average price of $36.0174 per share, with individual sale prices ranging from $35.82 to $36.28.
• The sale was executed on October 6, 2025, pursuant to a Rule 10b5-1 plan adopted by Mr. Febbo on September 4, 2024.
• Following this transaction, Mr. Febbo beneficially owns 92,441 shares of Veracyte common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a pre-scheduled insider sale under a 10b5-1 plan, which is a common and often pre-planned liquidity event for executives, rather than a reaction to new company-specific information.

Negatives

• The Chief Scientific & Medical Officer sold 8,349 shares of common stock, which could be perceived as a lack of confidence, although the sale was executed under a pre-arranged Rule 10b5-1 plan.

Industry Context

This filing reports a routine insider transaction under a pre-arranged plan, which is a common practice for executives to manage personal finances and diversify holdings. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: May observe the insider sale, but the 10b5-1 plan context generally mitigates concerns about management's confidence in the company's future.

Key Dates

Keywords

Veracyte, VCYT, Insider Sale, Form 4, 10b5-1 Plan, Phillip G. Febbo, Stock Transaction